Translational Drug Development (TD2)
Dawn Moris is a seasoned clinical data management professional with extensive experience in the pharmaceutical industry. Currently serving as a Senior Clinical Data Manager at Translational Drug Development (TD2) since December 2016, Dawn previously held multiple roles at Covance from July 2000 to December 2016, including Clinical Data Manager and Clinical Data Associate. Dawn began a career at Covance Laboratories as a Research Assistant, Analyst, and Sample Entry Coordinator. Educational qualifications include a Bachelor of Applied Science in Chemistry from the University of Wisconsin-Whitewater and a Bachelor of Applied Science in Biology from UW-Green Bay.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.